This is an international, open-label, stratified randomized controlled trial with Bayesian adaptive stopping rules to compare the effects of therapeutic-dose heparin vs. usual care pharmacological thromboprophylaxis on outcomes in patients admitted to hospital with community acquired pneumonia (CAP).
Patients ≥18 years of age
Radiographic evidence of new or worsening infiltrate
One or more of the following signs and/or symptoms of lower respiratory tract infection
Requires supplemental oxygen to treat hypoxemia (or requires an increased level of supplemental oxygen if on chronic oxygen therapy)
Suspected or confirmed active COVID-19 infection
Hospital admission for >72 hours prior to randomization
Patients receiving non-invasive or invasive ventilation, vasopressors, or extracorporeal life support (ECLS) within an ICU at the time of enrollment
Requirement for chronic mechanical ventilation via tracheostomy prior to hospitalization
University of Manitoba
Lead sponsor
Canadian Institutes of Health Research (CIHR)
Collaborator
Research Manitoba
Collaborator
Ozmosis Research Inc.
Collaborator
Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network
Collaborator
Canadian Critical Care Trials Group
Collaborator
Avanti PC
Collaborator
Aurora Clinical Research
Collaborator